Septerna, Inc. (SEPN) Stock Price & How to Invest

Septerna, Inc. designs oral small molecule drugs against G protein-coupled receptors, the receptor family that sits behind roughly a third of approved medicines but which has historically been drugged with injectables or with molecules found by luck rather than by design. Its Native Complex Platform reconstitutes GPCRs outside the cell in a form stable enough to screen and to solve structurally, which is what lets the company go after targets that are usually reached with peptides or antibodies. Three efforts define the pipeline in 2026: SEP-631, an oral MRGPRX2 antagonist aimed at chronic spontaneous urticaria; SEP-479, a next-generation oral PTH1R agonist for hypoparathyroidism; and a global collaboration with Novo Nordisk on oral GPCR programs in obesity, type 2 diabetes and other cardiometabolic disease. The company listed on the Nasdaq in October 2024 with an upsized IPO that raised about $288 million.

The financial shape is unusual for a company at this stage. Trailing twelve-month revenue is roughly $99 million, essentially all of it collaboration revenue recognized from the Novo Nordisk agreement rather than product sales, and that inflow has held the trailing net loss to about $24 million against a cash balance near $516 million. Management guides that cash into 2029, which is a long horizon by clinical-stage standards and removes the near-term financing pressure that usually dictates when these companies raise. What the market is pricing at a roughly $2.2 billion capitalization is the pipeline, not the revenue line. The stock has moved accordingly: it traded near $10.62 at the low end of the past year, closed around $47.76 on August 11, 2026 after a 23% single-day move around second-quarter results and a round of analyst target increases, and carries the memory of February 2025, when the discontinuation of the original PTH1R candidate SEP-786 cut the share price 47% in one session.

Every clinical-stage biotech carries binary risk, and here it has already been demonstrated: SEP-786 was discontinued in February 2025 after two severe cases of elevated unconjugated bilirubin, and the stock fell 47% that day. Several plaintiffs' firms announced investigations in the weeks after, which is a routine response to a drop of that size and did not produce a widely reported class action, but the episode is the clearest illustration of how this name trades on single data points. Revenue is collaboration accounting rather than product sales, so it is not a floor under the valuation, and Novo Nordisk can deprioritize programs. With roughly 46.7 million shares outstanding the float is small and daily moves of 20% in either direction are ordinary. Both target markets are contested, hypoparathyroidism by Ascendis and AstraZeneca with approved or late-stage injectables and chronic spontaneous urticaria by several biologics and oral candidates, so positive data still has to clear a commercial bar rather than an empty field.

9 analysts publish price targets on SEPN, averaging $45.44 against a $47.76 price as of August 2026, or -4.9%. The published targets run from $38.00 to $60.00, a moderate spread, and the ratings split 10 buy, 0 hold, 0 sell. Over the last six months there have been 8 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full SEPN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Septerna, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The Novo Nordisk collaboration. The partnership covers oral small molecule programs against specified GPCR targets in obesity, type 2 diabetes and related cardiometabolic disease, and it is the source of nearly all reported revenue. The most optimistic published target, $60.00, assumes this works close to its best case.

The case against. Every clinical-stage biotech carries binary risk, and here it has already been demonstrated: SEP-786 was discontinued in February 2025 after two severe cases of elevated unconjugated bilirubin, and the stock fell 47% that day. The most pessimistic target, $38.00, is roughly what SEPN is worth if this bites instead.

Read the full bull and bear case on SEPN, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Septerna, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$99 million, essentially all collaboration revenue from Novo Nordisk rather than product sales
• Revenue (Q2 2026): ~$26.8 million versus consensus near $19.2 million
• Net loss (TTM): ~$24 million, or about $0.54 per share
• Cash: ~$516.5 million at June 30, 2026, guided to fund operations at least into 2029
• Market cap: ~$2.2 billion (~46.7 million shares, recently near $48)
• 52-week range: ~$10.62 to ~$48.00

Price to sales of roughly 22 times shows up on screeners, but the denominator is partnership revenue on a recognition schedule, so the ratio does not describe a commercial business and comparing it to a specialty pharma multiple is not meaningful. The more useful framing is enterprise value: about $2.2 billion of market cap against roughly $516 million of cash leaves close to $1.7 billion attributed to a pipeline whose most advanced asset is entering Phase 2b. Analysts covering the stock are clustered around $49 to $51 after the August 2026 target raises, which is close to where the shares already trade.

Other names that sit close to SEPN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get SEPN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so SEPN sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where SEPN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Septerna is a funded, partnered, pre-commercial biotech whose share price is a running bet on clinical data, and the 2025 discontinuation of its original lead program is the reason that bet has to be sized carefully.

Whether SEPN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is SEPN a buy or a sell?, and where the stock could go from here in the SEPN stock forecast.

For income investors, whether SEPN pays a dividend and how the payout looks is covered in does SEPN pay a dividend? And to weigh SEPN against a peer, read the full side-by-side comparisons: SEPN vs VKTX and SEPN vs NVO.